We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Citius Pharmaceuticals Inc | NASDAQ:CTXR | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.705 | 0.6879 | 0.705 | 0.7359 | 0.67 | 0.7129 | 1,435,278 | 00:24:06 |
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue.
See
Instruction 1(b).
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
|
OMB APPROVAL
OMB Number: 3235-0287 Estimated average burden hours per response... 0.5 |
|
|
|
1. Name and Address of Reporting Person
*
Mazur Leonard L |
2. Issuer Name
and
Ticker or Trading Symbol
Citius Pharmaceuticals, Inc. [ CTXR ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__ X __ Director __ X __ 10% Owner __ X __ Officer (give title below) _____ Other (specify below) Executive Chairman |
C/O CITIUS PHARMACEUTICALS, INC., 11 COMMERCE DRIVE, 1ST FLOOR |
3. Date of Earliest Transaction
(MM/DD/YYYY)
|
|
CRANFORD, NJ 07016 |
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_ X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person |
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned |
||||||||||
1.Title of Security
(Instr. 3) |
2. Trans. Date | 2A. Deemed Execution Date, if any |
3. Trans. Code
(Instr. 8) |
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) |
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) |
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |||
Code | V | Amount | (A) or (D) | Price | ||||||
Common Stock | 4/3/2019 | P | 1165048 | A | $1.545 | 8020643 | D |
Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) |
|||||||||||||||
1. Title of Derivate Security
(Instr. 3) |
2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any |
4. Trans. Code
(Instr. 8) |
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) |
6. Date Exercisable and Expiration Date |
7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) |
8. Price of Derivative Security
(Instr. 5) |
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | ||||
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||||||
Options to Purchase Common Stock (1) | $3.45 | (1) | 9/13/2027 | Common Stock | 40000 | 40000 | D | ||||||||
Warrant to Purchase Common Stock (2) | $6.15 | (2) | 6/12/2019 | Common Stock | 19614 | 19614 | D | ||||||||
Warrant to Purchase Common Stock (2) | $9.9 | (2) | 9/30/2019 | Common Stock | 3171 | 3171 | D | ||||||||
Warrant to Purchase Common Stock (2) | $9.9 | (2) | 1/8/2020 | Common Stock | 4984 | 4984 | D | ||||||||
Warrant to Purchase Common Stock (2) | $7.5 | (2) | 8/18/2020 | Common Stock | 35211 | 35211 | D | ||||||||
Warrant to Purchase Common Stock (2) | $7.5 | (2) | 11/2/2020 | Common Stock | 20783 | 20783 | D | ||||||||
Warrant to Purchase Common Stock (2) | $7.5 | (2) | 11/20/2020 | Common Stock | 20664 | 20664 | D | ||||||||
Warrant to Purchase Common Stock (2) | $7.5 | (2) | 1/8/2021 | Common Stock | 13679 | 13679 | D | ||||||||
Warrant to Purchase Common Stock (2) | $7.5 | (2) | 3/14/2021 | Common Stock | 4210 | 4210 | D | ||||||||
Warrant to Purchase Common Stock (2) | $6.15 | (2) | 3/15/2021 | Common Stock | 18106 | 18106 | D | ||||||||
Warrant to Purchase Common Stock | $4.125 | (2) | 8/8/2022 | Common Stock | 421400 | 421400 | D | ||||||||
Warrant to Purchase Common Stock | $4.125 | (2) | 8/8/2022 | Common Stock | 11000 | 11000 | D | ||||||||
Options to Purchase Common Stock (3) | $6.75 | (3) | 9/12/2024 | Common Stock | 220000 | 220000 | D | ||||||||
Warrant to Purchase Common Stock (2) | $4.63 | (2) | 6/19/2023 | Common Stock | 106553 | 106553 | D | ||||||||
Warrant to Purchase Common Stock (2) | $2.86 | (2) | 9/29/2023 | Common Stock | 167504 | 167504 | D | ||||||||
Warrant to Purchase Common Stock (2) | $1.15 | (2) | 8/14/2023 | Common Stock | 3137255 | 3137255 (4) | D | ||||||||
Options to Purchase Common Stock (5) | $1.62 | (5) | 9/4/2028 | Common Stock | 150000 | 150000 | D | ||||||||
Warrant to Purchase Common Stock (2) | $1.42 | 4/3/2019 | P | 1165048 | (2) | 4/5/2021 | Common Stock | 1165048 | (4) | 1615048 | D |
Reporting Owners
|
|||||
Reporting Owner Name / Address |
|
||||
Director | 10% Owner | Officer | Other | ||
Mazur Leonard L
C/O CITIUS PHARMACEUTICALS, INC. 11 COMMERCE DRIVE, 1ST FLOOR CRANFORD, NJ 07016 |
X | X | Executive Chairman |
|
Signatures
|
||
/s/ Alexander M. Donaldson, by power of attorney | 4/5/2019 | |
** Signature of Reporting Person |
Date
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | |
* | If the form is filed by more than one reporting person, see Instruction 4(b)(v). |
** | Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
Note: | File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. |
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. |
1 Year Citius Pharmaceuticals Chart |
1 Month Citius Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions